NovoCure Limited (NVCR)

NovoCure Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	621.71	605.22	509.34	537.84	535.03	494.37
Revenue Growth (YoY)	18.27%	18.82%	-5.30%	0.53%	8.23%	40.72%
Cost of Revenue	141.01	136.18	127.54	114.26	114.24	106.09
Gross Profit	480.7	469.05	381.8	423.58	420.79	388.27
Selling, General & Admin	433.04	427.21	386.97	306.41	263.18	225.45
Research & Development	211.55	209.37	220.99	206.09	201.3	132.01
Operating Expenses	644.59	636.58	607.96	512.5	464.49	357.46
Operating Income	-163.88	-167.54	-226.16	-88.91	-43.69	30.81
Interest Expense	-10.34	-10.34	-3.32	-3.33	-3.44	-17.58
Interest & Investment Income	20.42	22.72	19.64	10.96	0.79	1.79
Currency Exchange Gain (Loss)	-0.72	-0.72	-0.8	-3.52	-4.03	2.65
Other Non Operating Income (Expenses)	-0.6	-0.6	-0.79	-1.26	-1.37	-0.47
EBT Excluding Unusual Items	-155.13	-156.48	-211.42	-86.06	-51.74	17.2
Merger & Restructuring Charges	-2	-2	-6.23	-	-	-
Gain (Loss) on Sale of Investments	28.27	28.27	26.4	4.83	0.31	1.32
Asset Writedown	-0.95	-0.95	-0.48	-0.61	-0.64	-0.41
Pretax Income	-129.82	-131.16	-191.74	-81.85	-52.08	18.1
Income Tax Expense	34.37	37.47	15.3	10.69	6.28	-1.71
Net Income	-164.19	-168.63	-207.04	-92.53	-58.35	19.81
Net Income to Common	-164.19	-168.63	-207.04	-92.53	-58.35	19.81
Shares Outstanding (Basic)	109	108	106	105	103	101
Shares Outstanding (Diluted)	109	108	106	105	103	109
Shares Change (YoY)	1.68%	1.36%	1.65%	1.19%	-5.00%	11.97%
EPS (Basic)	-1.51	-1.56	-1.95	-0.88	-0.56	0.20
EPS (Diluted)	-1.51	-1.56	-1.95	-0.88	-0.56	0.18
Free Cash Flow	-72.14	-69.22	-100.43	9.43	58.59	84.18
Free Cash Flow Per Share	-0.66	-0.64	-0.94	0.09	0.57	0.77
Gross Margin	77.32%	77.50%	74.96%	78.76%	78.65%	78.54%
Operating Margin	-26.36%	-27.68%	-44.40%	-16.53%	-8.17%	6.23%
Profit Margin	-26.41%	-27.86%	-40.65%	-17.21%	-10.91%	4.01%
Free Cash Flow Margin	-11.60%	-11.44%	-19.72%	1.75%	10.95%	17.03%
EBITDA	-153.51	-157.67	-216.46	-79.34	-34.53	38.56
EBITDA Margin	-24.69%	-26.05%	-42.50%	-14.75%	-6.45%	7.80%
D&A For EBITDA	10.38	9.87	9.7	9.57	9.17	7.75
EBIT	-163.88	-167.54	-226.16	-88.91	-43.69	30.81
EBIT Margin	-26.36%	-27.68%	-44.40%	-16.53%	-8.17%	6.23%

Updated Apr 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q